Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Understanding SLE-Associated Skin Injury May Open the Door to Therapies

Lara C. Pullen, PhD  |  September 7, 2015

The authors ended their review article by describing several therapeutic targets that have the potential to control skin injury in SLE: TNF receptor superfamily member 1a, tyrosine-protein kinase SYK, calcium/calmodulin-dependent protein kinase type IV and nuclear factor of activated T cells.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Deng GM, Tsokos GC. Pathogenesis and targeted treatment of skin injury in SLE. Nat Rev Rheumatol. 2015 Aug 4. doi: 10.1038/nrrheum.2015.106. [Epub ahead of print]

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lupus nephritisskinskin inflammationsystemic lupus erythematosus (SLE)ultraviolet light

Related Articles

    Rheum After 5: Dr. George Tsokos Shares His Love & Friendship with a Cat

    October 19, 2020

    George C. Tsokos, MD, professor of medicine at Harvard Medical School and chief of the Division of Rheumatology, Beth Israel Deaconess Medical Center, both in Boston, doesn’t recall the moment he first became infatuated with Little, a 12-year-old Siamese cat. Dr. Tsokos doesn’t even own Little. Not that anyone can truly own any living creature….

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Protein Phosphatase 2A and Regulatory T Cell Function Researched

    June 13, 2016

    The serine-threonine protein phosphatase 2A (PP2A) enzyme is critical for regulatory T cells to function—without it, they don’t have the ability to suppress effector T cells and can’t protect against autoimmunity, according to new research published in Nature Immunology. Researchers found that conditional knockout mice—in which PP2A expression is knocked out only in regulatory T cells—developed…

    2014 ACR/ARHP Annual Meeting: Evelyn V. Hess Award Presentation

    February 1, 2015

    The Lupus Foundation of America bestows awards to Drs. Jane Salmon, George Tsokos for outstanding contributions to research

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences